ABVC BioPharma, Inc. — Q1 2024 Form 10-Q
Business context and reporting period. This unaudited filing covers the three months ended March 31, 2024, compared with Q1 2023. ABVC is a clinical-stage biotechnology company developing plant-derived drugs and medical devices, alongside BioKey’s contract development and manufacturing services. Its common stock trades on Nasdaq under ABVC.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | $1,205 | $128,272 |
| Gross profit | $928 | $68,036 |
| Operating expenses | $3.445 million | $1.974 million |
| Operating loss | $(3.444) million | $(1.906) million |
| Net loss | $(3.981) million | $(1.897) million |
| Net loss attributable to ABVC | $(3.933) million | $(1.824) million |
| Basic and diluted loss per share | $(0.40) | $(0.55) |
| Operating cash flow | $(473,161) | $(1.498) million |
| Cash and cash equivalents, March 31 | $30,489 | $60,155 at Dec. 31, 2023 |
| Restricted cash, March 31 | $628,513 | $656,625 at Dec. 31, 2023 |
| Total assets, March 31 | $14.460 million | $14.493 million at Dec. 31, 2023 |
| Total liabilities, March 31 | $6.973 million | $6.362 million at Dec. 31, 2023 |
Revenue fell about 99%, which management attributed to completed projects and waiting for new approvals. Operating expenses rose 75%, mainly because stock-based compensation increased to $2.545 million from $366,489; lower SG&A and R&D partially offset the increase. Interest expense was $684,683, including substantial noncash expense associated with convertible notes. Foreign-exchange gains were $113,520, compared with a loss of $12,261 in Q1 2023.
Operating cash use improved year over year, but cash and restricted cash together declined by $57,778 to $659,002, including a $260,783 adverse exchange-rate effect. Financing provided $676,166, including convertible-note proceeds and warrant proceeds. Current assets were $1.794 million versus current liabilities of $6.634 million, a reported working-capital deficit of $4.839 million. Current debt included $860,750 of short-term bank loans and $842,567 of convertible notes, net. The filing reports no income tax provision.
Material changes and notable items
- Net loss increased 110% year over year, while weighted-average shares rose to 9.736 million from 3.308 million. Common shares outstanding were 10,698,315 at quarter-end, versus 7,940,298 at year-end 2023; 10,851,823 were reported outstanding on May 10, 2024.
- The company issued a $1.0 million principal secured convertible note to Lind in January 2024 for $833,333, with warrants and variable-price conversion provisions. It also issued 751,795 shares to settle $681,000 of convertible debt during the quarter. The notes carry dilution and default risks; certain conversion terms include a $1.00 floor and cash compensation if the conversion price reaches that floor.
- Stockholders’ equity declined to $7.487 million from $8.131 million. The filing identifies goodwill as impaired based on the company’s financial condition and uncertain prospects for future operating income; it does not provide a clear impairment amount in the supplied text.
- ABVC’s $7.4 million construction-in-progress balance relates to its reported 20% interest in a property in China. Government ownership certification remains in process; the project was planned for completion before the end of 2024.
Outlook, risks and contingencies
- Going concern: Management states that substantial doubt exists about the company’s ability to continue as a going concern, citing the Q1 net loss, $4.839 million working-capital deficit and operating cash outflow. Its plans are to improve operations and raise capital through private or public offerings; success is not assured.
- Pipeline: Management described an ABV-1505 ADHD Phase II Part 2 interim analysis as in progress and expected Phase I work for ABV-1601 in Q2 2024. ABV-1519 and ABV-1703 studies were expected to begin in Q3 2024. These are plans, not reported outcomes. The Vitargus Phase II study had serious adverse events at Thailand sites; the company said it was investigating causes and working on a safer procedure before resuming. Development of ABV-2002 was also on hold for lack of funding.
- Potential licensing income: A March 2024 global, 20-year ophthalmology license with ForSeeCon and post-quarter OncoX agreements could provide fees and royalties, but amounts and timing are contingent. The filing describes payments, funding and commercial milestones that are not guaranteed; no such prospective amounts should be treated as realized revenue.
- Related-party exposure: Due from related parties was $887,937 current and $123,363 non-current, net, at March 31. This includes a $346,565 loan to BioFirst at 12% and a $541,372 current receivable from Rgene; the expected-credit-loss allowance against BioFirst (Australia) was $839,983. Several investees and counterparties are related parties.
- Controls and legal matters: Management concluded disclosure controls were not effective at March 31 due to a material weakness identified in the 2023 Form 10-K; it reported no change in internal control during the quarter. The company reported no legal proceedings expected to have a material adverse effect and no defaults upon senior securities.
- Other risks include customer concentration (one customer accounted for 100% of Q1 revenue), dependence on additional financing, possible dilution and Lind-note default provisions, clinical and regulatory uncertainty, foreign-exchange exposure, and uncertain recovery of related-party balances and investments. No specific financial guidance was provided.
Key facts investors should verify
- Whether ABVC can secure sufficient financing and address its disclosed going-concern doubt and working-capital deficit.
- The outstanding principal, conversion activity, cash-payment obligations, and potential dilution under Lind’s secured convertible notes and warrants, including the status of any market-capitalization-related waiver or default provisions.
- Progress and safety findings for Vitargus, the ABV-1505 interim analysis, and the clinical programs scheduled to start in 2024.
- Whether licensing counterparties make the stated payments, satisfy milestones, and advance development; the agreements alone do not establish collectible revenue.
- Collection and recoverability of related-party receivables and investments, and the status of Chinese property certification and development.
- Remediation of the material weakness in disclosure controls and the basis and amount of the goodwill impairment.